Leflunomide inhibits dihydroorotate
dehydrogenase and thereby blocks the de novo pathway of pyrimidine nucleotide synthesis, which is crucial for T-cell activation and proliferation.
2234 2104679 T T G SP70585_2289 Position Gene product Synonymous 384518 Hypothetical protein No 425383 Helicase, RecD/TraA family No 457503 Not applicable -- 568204 Not applicable -- 923459 Dihydroorotate
dehydrogenase 1B No 936681 Competence protein No 1389846 Pyridoxal biosynthesis lyase PdxS No 1675901 Preprotein translocase subunit SecY No 2044455 # beta-N-Acetylglucosaminidase/ No beta-glucosidase (3- beta-N-acetyl-D- glucosaminidase/ beta-D-glucosidase) (Nag3) 2104679 alpha-L-Fucosidase No Position Amino acid change 384518 K [right arrow] * 425383 R [right arrow] H 457503 -- 568204 -- 923459 S [right arrow] A 936681 K [right arrow] N 1389846 E [right arrow] * 1675901 T [right arrow] I 2044455 # E [right arrow] A 2104679 S [right arrow] R # SNV is located in the genomic island.
Teriflunomide a selective immunosuppressant with anti-inflammatory properties inhibits lymphocyte proliferation by blocking dihydroorotate
dehydrogenase which is the rate limiting step in pyrimidine synthesis.
This agent works by inhibiting dihydroorotate
dehydrogenase, which is necessary for deoxyribonucleic acid replication.
It inhibits the mitochondrial enzyme dihydroorotate
dehydrogenase, which plays a role in pyrimidine synthesis interfering with T- and B-cell proliferation.
4SC-101, a novel small molecule dihydroorotate
dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice.
10) Leflunomide inhibits an enzyme in the pyrimidine pathway, dihydroorotate
Mechanism of action of leflunomide in the treatment of RA is selectively inhibition of enzyme dihydroorotate
dehydrogenase that is necessary for the de novo pyrimidine synthesis (2).
Researchers at the University of Leeds say that the compounds work by preventing the enzyme dihydroorotate
dehydrogenase (DHODH) - essential to the growth of the parasite - from working, which results in its death.
20) It suppresses immune cells by inhibiting dihydroorotate
dehydrogenase, an enzyme necessary for the production of DNA and RNA, thereby suppressing proliferation of lymphocytes.
The addition of dichloroallyl lawsone (DCL) to leukemic cells results in a rapid depletion of uridine and cytidine nucleotides; carbamyl aspartate and dihydroorotate
accumulate to high levels in an equilibrium ratio of 20.
This blockade results in the repression of pyrimidine biosynthesis by the inhibition of dihydroorotate